A revision of sexual mixing matrices in models of sexually transmitted infection

Statistics in Medicine

Volumn 31, Issue 27, 2012, Pages 3419-3432

  Walker, Robert ^a   Nickson, Carolyn ^a,b   Lew, Jie Bin ^a   Smith, Megan ^a   Canfell, Karen ^a,c  

^a CANCER RESEARCH DIVISION   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c UNIVERSITY OF SYDNEY   (Australia)

Author keywords

HPV; HPV vaccination; Mixing matrix; Sexual behaviour; STI modelling

Indexed keywords

WART VIRUS VACCINE;

ARTICLE; DISEASE ASSOCIATION; GROUPS BY AGE; HUMAN; INTERMETHOD COMPARISON; MATHEMATICAL COMPUTING; MATHEMATICAL MODEL; PAPILLOMAVIRUS INFECTION; POPULATION MODEL; PREDICTION; PREVALENCE; PROBABILITY; PROCESS DEVELOPMENT; RELIABILITY; SEXUAL BEHAVIOR; SEXUAL MIXING MATRIX; SEXUALLY TRANSMITTED DISEASE; SYSTEMATIC ERROR; VIRUS TRANSMISSION; WART VIRUS;

AGE FACTORS; AUSTRALIA; COMPUTER SIMULATION; DATA INTERPRETATION, STATISTICAL; FEMALE; HUMANS; MALE; MODELS, STATISTICAL; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; SEX FACTORS; SEXUAL PARTNERS;

EID: 84869052053     PISSN: 02776715     EISSN: 10970258     Source Type: Journal    
DOI: 10.1002/sim.5545     Document Type: Article

References (25)

1. Garnett GP, Anderson RM. Factors controlling the spread of HIV in heterosexual communities in developing countries: patterns of mixing between different age and sexual activity classes. Philosophical Transactions of the Royal Society of London. Series B, Biological Sciences 1993; 342(1300):137-159.
2. Gupta S, Anderson RM, May RM. Networks of sexual contacts: implications for the pattern of spread of HIV. AIDS 1989; 3(12):807-817.
3. Renton A, Whitaker L, Ison C, Wadsworth J, Harris JR. Estimating the sexual mixing patterns in the general population from those in people acquiring gonorrhoea infection: theoretical foundation and empirical findings. Journal of Epidemiology and Community Health 1995; 49(2):205-213.
4. Renton AM, Whitaker L, Riddlesdell M. Heterosexual HIV transmission and STD prevalence: predictions of a theoretical model. Sexually Transmitted Infections 1998; 74(5):339-344.
5. Anderson RM, May RM, Ng TW, Rowley JT. Age-dependent choice of sexual partners and the transmission dynamics of HIV in sub-Saharan Africa. Philosophical Transactions of the Royal Society of London. Series B, Biological Sciences 1992; 336(1277):135-155.
6. French K, Riley S, Garnett G. Simulations of the HIV epidemic in sub-Saharan Africa: sexual transmission versus transmission through unsafe medical injections. Sexually Transmitted Diseases 2006; 33(3):127-134.
7. van de Velde N, Brisson M, Boily MC. Understanding differences in predictions of HPV vaccine effectiveness: a comparative model-based analysis. Vaccine 2010; 28(33):5473-5484.
8. Garnett GP, Anderson RM. Balancing sexual partnerships in an age and activity stratified model of HIV transmission in heterosexual populations. IMA Journal of Mathematics Applied in Medicine & Biology 1994; 11(3):161-92.
9. Smith MA, Canfell K, Brotherton JM, Lew JB, Barnabas RV. The predicted impact of vaccination on human papillomavirus infections in Australia. International Journal of Cancer 2008; 123(8):1854-1863.
10. Barnabas RV, Laukkanen P, Koskela P, Kontula O, Lehtinen M, Garnett GP. Epidemiology of HPV 16 and cervical cancer in Finland and the potential impact of vaccination: mathematical modelling analyses. PLoS Medicine/Public Library of Science 2006; 3(5):624-632.
11. Elbasha EH, Dasbach EJ, Insinga RP. A multi-type HPV transmission model. Bulletin of Mathematical Biology 2008; 70(8):2126-2176.
12. Nold A. Heterogeneity in disease-transmission modeling. Mathematical Biosciences 1980; 52(3-4):227-240.
13. Smith MA, Lew JB, Walker RJ, Brotherton JM, Nickson C, Canfell K. The predicted impact of HPV vaccination on male infections and male HPV-related cancers in Australia. Vaccine 2011; 29(48):9112-9122.
14. Garland SM, Brotherton JM, Condon JR, McIntyre PB, Stevens MP, Smith DW, Tabrizi SN. Human papillomavirus prevalence among indigenous and non-indigenous Australian women prior to a national HPV vaccination program. BMC Medicine 2011; 9:104.
15. Gertig DM, Brotherton JML, Saville AM. Measuring human papillomavirus (HPV) vaccination coverage and the role of the National HPV Vaccination Program Register, Australia. Sexual Health 2011; 8:171-178.
16. Kim JJ, Andres-Beck B, Goldie SJ. The value of including boys in an HPV vaccination programme: a cost-effectiveness analysis in a low-resource setting. British Journal of Cancer 2007; 97(9):1322-1328.
17. Regan DG, Philp DJ, Hocking JS, Law MG. Modelling the population-level impact of vaccination on the transmission of human papillomavirus type 16 in Australia. Sexual Health 2007; 4(3):147-163.
18. Kim JJ, Brisson M, Edmunds WJ, Goldie SJ. Modeling cervical cancer prevention in developed countries. Vaccine 2008; 26 Suppl 10:K76-K86.
19. Marra F, Cloutier K, Oteng B, Marra C, Ogilvie G. Effectiveness and cost effectiveness of human papillomavirus vaccine: a systematic review. Pharmacoeconomics 2009; 27(2):127-147.
20. Brisson M, Van de Velde N, Boily MC. Economic evaluation of human papillomavirus vaccination in developed countries. Public Health Genomics 2009; 12(5-6):343-351.
21. Kulasingam S, Connelly L, Conway E, Hocking JS, Myers E, Regan DG, Roder D, Ross J, Wain G. A cost-effectiveness analysis of adding a human papillomavirus vaccine to the Australian National Cervical Cancer Screening Program. Sexual Health 2007; 4(3):165-175.
22. Anonychuk AM, Bauch CT, Merid MF, Van Kriekinge G, Demarteau N. A cost-utility analysis of cervical cancer vaccination in preadolescent Canadian females. BMC Public Health 2009; 9:401.
23. Kim JJ, Goldie SJ. Cost effectiveness analysis of including boys in a human papillomavirus vaccination programme in the United States. BMJ 2009; 339:b3884. DOI: 10.1136/bmj.b3884.
24. Jit M, Chapman R, Hughes O, Choi YH. Comparing bivalent and quadrivalent human papillomavirus vaccines: economic evaluation based on transmission model. BMJ 2011; 343:d5775, DOI: 10.1136/bmj.d5775.
25. Elbasha EH, Dasbach EJ. Impact of vaccinating boys and men against HPV in the United States. Vaccine 2010; 28(42):6858-6867.